Skip to content
Hemophilia and gene therapy
12th ECAT International Symposium 2022
Speaker
Titel
Abstract
Presentation
video
F. Leebeek
Hemophilia and gene therapy
Related items
Analytical Information :
7
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
6
A patient with mild haemophilia A
Haemophilia B and treatment, case study
Haemophilia A and treatment, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
ECAT Documents :
46
Intrinsic Pathway of Coagulation
Inhibitor
Hemophilia B
Hemophilia A
Factor IX Concentrates
Factor IX (FIX)
Factor VIII (FVIII)
Extrinsic Pathway of Coagulation
Desmopressin Acetate (DDAVP)
Coumarin
Coagulation Factors
Bethesda Inhibitor Assay (Titer)
Laboratory issues related to the measurement of efanesoctocog alfa webinar 2025
Analytical variation in factor VIII one‐stage and chromogenic assays: Experiences from the ECAT external quality assessment programme
Performance of factor IX extended half-life product measurements in external quality control assessment programs
The results of the workshop on inhibitor testing
Inhibitor testing: positive or negative? True or False?
The laboratory diagnosis of vWD: current insights
Factor VIII Inhibitor Testing, the way to better comparison of test results
Case studies in Bleeding disorders
Towards diagnostic quality control: a pilot study on acquired inhibitors
Factor VIII inhibitor testing – a way to comparable test results
The performance of FVIII and FIX measurement in ECAT surveys
Laboratory assays for the measurement of Factor VIII and IX
Gene therapy, the future in hemophilia treatment?
The role of molecular biology in the diagnosis of impaired haemostasis
Introduction on Inhibitor Testing
ECAT survey results for low levels of Factor VIII
How to measure low levels of Factor VIII and IX
Introduction on Inhibitor Testing
Haemophilia, new development in patient treatment
Quality Assurance of extended half-life products
Laboratory measurement of extended half-life FVIII
Laboratory measurement of extended half-life FIX
Potency labelling of extended half-life FVIII en FIX products
Treatmentof patients with extended half-life FVIII and FIX products
Factor VIII testing: results of ECAT surveys
One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients
Haemophilia treatment and laboratory testing
New developments in haemophilia treatment
What information does the doctor expect from the laboratory? What kind of services can a laboratory deliver to the physician?
When Haemostasis Assays Mislead
Guidance for FVIII/FIX Inhibitor testing
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors
Guidelines :
1
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
4
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Quality Assurance of replacement therapy and future perspectives
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Surveys and Studies :
3
Emicizumab pilot study, part II
Emicizumab pilot study, part I
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Questions or suggestions?
Clotpedia Support Form
Submit
Success
